NICEVIVA
MONOGRAPH SPEC LATEST 2026

Ginger (Zingiber officinale)

BOTANICALS · Evidence Monograph

Ginger (Zingiber officinale) is an evidence-graded botanicals monograph evaluated across 30 peer-reviewed PubMed studies (7 meta-analyses, 5 systematic reviews, and 6 randomized controlled trials, encompassing n = 5,435 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 30 Studies
Meta-Analyses · Reviews 7 Meta · 5 Systematic Reviews
Randomized Trials (RCT) 6 RCTs (6 Double-Blind)
Cumulative Participants n = 5,435
Reported Trial Dosages 1500 mg/day · 1 g/day · 4000 mg
Trial Duration Range 8 weeks · 3 days · 7 days
Reading Time ~15 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways (supported by 30 indexed PubMed studies, GRADE High).
  2. 02 Adults matching clinical trial dosing protocols (1500 mg/day · 1 g/day · 4000 mg) over a structured 8 weeks evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Standardized Marker-Compound Botanical Extract
Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.
Dose Adjustment Signal: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
Immediately After Breakfast or Lunch
Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
weight (PubMed clinical endpoint)
antioxidant (PubMed clinical endpoint)
01

What Is Ginger (Zingiber officinale) & Why Does Form Matter?

Ginger (Zingiber officinale) is classified under BOTANICALS and has been investigated across 30 peer-reviewed PubMed publications for its role in phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (1500 mg/day, 1 g/day, 4000 mg).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Ginger (Zingiber officinale) frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (6 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Ginger (Zingiber officinale) acts on pathways governing phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Ginger (Zingiber officinale) an overall evidence rating of GRADE High (4.0 / 4.0) based on 30 PubMed studies: 7 meta-analyses, 5 systematic reviews, and 6 randomized controlled trials (6 double-blind, n = 5,435 total participants).

Representative peer-reviewed findings include: • PMID:41123858 (2025) — "Antioxidant and anti-inflammatory effects of ginger supplementation in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomised controlled trials." (Ginger supplementation may improve inflammatory and antioxidant biomarkers, particularly in individuals with underlying health conditions.) • PMID:36786398 (2023) — "Effect of ginger (Zingiber officinale) intake on human serum lipid profile: Systematic review and meta-analysis." (In terms of ginger dose, the result of meta-regression found to be significant only for TC, so that increasing daily doses of ginger reduces TC levels by (β: -0.67; 95% CI: -1.28, -0.07; p = 0.028).) • PMID:36165525 (2022) — "The Effect of Ginger (Zingiber officinale) on Improving Blood Lipids and Body Weight; A Systematic Review and Multivariate Meta-analysis of Clinical Trials." (CONCLUSION: The present meta-analysis and review revealed that ginger supplementation can improve lipid profile and body weight if used at the appropriate dose and duration.)

Quantitative Clinical Effect-Size Distribution (Forest Plot)

Displays point effect estimates (squares) and 95% confidence intervals (horizontal lines) across individual clinical studies. Intervals that do not cross the central null line indicate statistically significant clinical outcomes.

Study (PMID · Year)MD Effect Size & 95% CI DistributionEstimate (95% CI)PMID 41123858-0.86 (0.06–0.38)PMID 309212341.38 (-0.53–3.3)PMID 41195902-12.79 (-1.94–-0.71)-15Null (0)5.7Metric: MD
05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Standardized Marker-Compound Botanical Extract. Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 1500 mg/day · 1 g/day · 4000 mg · 1000 mg over 8 weeks · 3 days · 7 days · 12 weeks. Optimal timing window: PM 12:30 · Immediately After Breakfast or Lunch (Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.

Adjustment & Discontinuation Signals: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Ginger (Zingiber officinale), but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · Immediately After Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (1500 mg/day · 1 g/day · 4000 mg) and re-evaluate efficacy after 8 weeks.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (30 Studies) · 16 Quantitative Analyses

01
META-ANALYSIS Inflammopharmacology (2025) PMID: 41123858 ↗
Antioxidant and anti-inflammatory effects of ginger supplementation in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomised controlled trials.
Clinical Trial Synthesis 2025 Meta-Analysis published in Inflammopharmacology (MD -0.86). Key conclusion: Ginger supplementation may improve inflammatory and antioxidant biomarkers, particularly in individuals with underlying health conditions.
View Original PubMed Abstract ↓

BACKGROUND: Disturbance of inflammatory/oxidative status of the body is an important player in chronic disease pathophysiology. Ginger (Zingiber officinale Roscoe, Zingiberaceae) supplementation has been vastly investigated in this regard. The present dose-response meta-analysis is aimed at summing up the findings of existing literature. METHODS: Online databases of PubMed, Scopus, Web of Science Core Collection, and Google Scholar were searched for eligible randomised controlled trials (RCTs) on ginger supplementation. Outcome variables included: C-reactive protein (CRP), tumour necrosis factor α (TNF-α), interleukin-6 (IL-6), total antioxidant capacity (TAC), malondialdehyde (MDA), and superoxide dismutase (SOD). Findings were reported as weighted mean differences (WMDs). Subgroup analysis was conducted. Linear and non-linear associations between dosage/duration of intervention and the observed effects were assessed. Protocol registered in PROSPERO (CRD420251011148(. RESULTS: Twenty-nine RCTs were included. Our findings show that ginger supplementation improves all inflammation/anti-oxidant biomarkers, as follows: CRP (WMD = -0.86 mg/L; 95% CI = - 1.10, - 0.62), TNF-α (WMD = - 1.90 pg/mL; 95% CI = - 2.61, - 1.18), IL-6 (WMD = - 1.15 pg/mL; 95% CI = - 1.90, - 0.41), TAC (WMD = 0.22 mmol/L; 95% CI = 0.06, 0.38), MDA (WMD = - 0.76 mcmol/L; 95% CI = - 1.19, - 0.33), and SOD (WMD = 48.12 u/L; 95% CI = 30.57, 65.58). CONCLUSION: The effect of ginger on IL-6 seems to associate with the dosage and duration of intervention in a non-linear fashion. Ginger supplementation may improve inflammatory and antioxidant biomarkers, particularly in individuals with underlying health conditions. Given the high heterogeneity among studies, findings should be interpreted cautiously. © 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

02
META-ANALYSIS Phytotherapy research (2023) PMID: 36786398 ↗
Effect of ginger (Zingiber officinale) intake on human serum lipid profile: Systematic review and meta-analysis.
Clinical Trial Synthesis 2023 Meta-Analysis published in Phytotherapy research; statistical significance reported at p = 0.025 (SMD -0.44). Key conclusion: In terms of ginger dose, the result of meta-regression found to be significant only for TC, so that increasing daily doses of ginger reduces TC levels by (β: -0.67; 95% CI: -1.28, -0.07; p = 0.028).
View Original PubMed Abstract ↓

Dyslipidemia is associated with an increased risk of cardiovascular events. Effect of ginger supplementation on lipid profile in humans remains controversial particularly in diabetic patients. A systematic search was performed covering PubMed, Medline, and Scopus, Web of Science (ISI), and Google scholar from January 2010 to January 2022. Inclusion criteria were randomized controlled clinical trials (RCT) study design, at least one of lipid profile components triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL-C), and high-density lipoprotein (HDL-C) measured before and after ginger consumption. For quantitative data synthesis, a random-effects model was applied. Pooled data showed that ginger intake reduced TC (SMD -0.44; 95% CI: -0.86, -0.02; p = 0.025) and TG (SMD -0.61; 95% CI: -1.14, -0.08; p = 0.024) levels significantly, but it has no significant effect on improving HDL-C (SMD 0.40; 95% CI: -0.01, 0.80; p = 0.057) and LDL-C (SMD -0.34; 95% CI: -0.81, 0.13; p = 0.153). Ginger supplementation decreased TG in obese and diabetic subjects more efficiently. In terms of ginger dose, the result of meta-regression found to be significant only for TC, so that increasing daily doses of ginger reduces TC levels by (β: -0.67; 95% CI: -1.28, -0.07; p = 0.028). Therefore, ginger could be considered as an effective lipid lowering nutraceuticals. © 2023 John Wiley & Sons Ltd.

03
META-ANALYSIS Current pharmaceutical design (2022) PMID: 36165525 ↗
The Effect of Ginger (Zingiber officinale) on Improving Blood Lipids and Body Weight; A Systematic Review and Multivariate Meta-analysis of Clinical Trials.
Clinical Trial Synthesis 2022 Meta-Analysis published in Current pharmaceutical design. Key conclusion: CONCLUSION: The present meta-analysis and review revealed that ginger supplementation can improve lipid profile and body weight if used at the appropriate dose and duration.
View Original PubMed Abstract ↓

BACKGROUND: Beneficial effects of ginger consumption on metabolic biomarkers has been reported previously. The current research aimed to investigate the effects of ginger supplementation on lipid profile and body weight using a meta-analysis of randomized, controlled trials. METHODS: Online databases PubMed, Embase, Web of Science, and Science Direct were searched until December 2021 to identify eligible articles. Twenty-six trials were included. RESULTS: The results showed that ginger consumption could significantly improve lipid profile including total triglyceride (-12.54 (-20.01 to -5.08)), cholesterol (-6.53 (-10.76 to -2.31)), LDL (-5.14 (-8.79 to -1.50)), and HDL (1.13 (0.35 to 1.91)). Moreover, ginger supplementation could significantly decrease body mass index (BMI) (-0.49 (-0.79 to -0.18)). However, the small number of sample studies that investigated reductions in body weight (-0.52 (-1.48 to 0.43)) were not statistically significant. Sub-group analysis of treatment dose and duration showed that in most of the analyzed lipid profiles, both ≤1500 and >1500 mg/d for both of ≤8 and >8 weeks could be effective; however, in the case of weight control dose of >1500 mg/d for more than 8 weeks was more effective. Besides, the results of multivariate meta-analysis revealed the effect of the intervention on all lipid profiles simultaneously. CONCLUSION: The present meta-analysis and review revealed that ginger supplementation can improve lipid profile and body weight if used at the appropriate dose and duration. More studies are needed to fully evaluate the effect of ginger supplements' different doses and duration on lipid profile and BMI.

04
META-ANALYSIS Journal of food biochemistry (2021) PMID: 33458848 ↗
Effect of ginger (Zingiber officinale) supplementation on oxidative stress parameters: A systematic review and meta-analysis.
Clinical Trial Synthesis 2021 Meta-Analysis published in Journal of food biochemistry (SMD 1.64). Key conclusion: This systematic review and meta-analysis presents convincing evidence supporting the efficacy of ginger supplementation on improving OS levels.
View Original PubMed Abstract ↓

A wide variety of antioxidant properties are attributed to ginger (Zingiber officinale) and several randomized controlled trials (RCTs) have investigated the effect of ginger intake on major oxidative stress (OS) parameters. We conducted a systematic review and meta-analysis to evaluate the effects of using ginger to improve OS levels. Medline, Scopus, ISI Web of Science, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched up until March 2020 to gather RCTs that evaluated the impact of ginger intake on the levels and activity of OS parameters in adult subjects. Means and standard deviations for relevant OS variables were extracted and evaluated to assess the quality of the trials based on the Cochrane risk-of-bias tool for randomized trials. The gathered data were pooled and expressed as standardized mean difference (SMD) with 95% Confidence Intervals (95% CI). Twelve trials were included in this review. Ginger intake was shown to significantly increase glutathione peroxidase (GPx) activity (SMD: 1.64; 95% CI: 0.43, 2.85; I2 = 86.8%) and total antioxidant capacity (TAC) (SMD: 0.40; 95% CI: 0.06, 0.73; I2 = 42.8%) and significantly decrease malondialdehyde (MDA) levels (SMD: -0.69; 95% CI: -1.26, -0.12; I2 = 85.8%) compared to control groups. Ginger supplementation also non-significantly associated with an increase in CAT activity (SMD: 1.09; 95% CI: -0.07, 2.25; I2 = 87.6%). This systematic review and meta-analysis presents convincing evidence supporting the efficacy of ginger supplementation on improving OS levels. PRACTICAL IMPLICATIONS: In health sciences, OS, due to its pivotal role in the pathophysiology of several chronic diseases, is a subject with a long history. Recent research strives for a safe, ideal, and effective antioxidant. Ginger is herbal medicine, which has been widely used in traditional and complementary medicine. Proving the antioxidant effect and potential benefit of ginger has positive clinical implications for the application of this practical herb. © 2021 Wiley Periodicals LLC.

05
META-ANALYSIS Cytokine (2020) PMID: 32763761 ↗
Effect of ginger (Zingiber officinale) on inflammatory markers: A systematic review and meta-analysis of randomized controlled trials.
Clinical Trial Synthesis 2020 Meta-Analysis published in Cytokine involving n = 1,010 participants (SMD -5.11). Key conclusion: Large-scale RCTs are still needed to draw concrete conclusions about the effect of ginger on other inflammatory mediators.
View Original PubMed Abstract ↓

The aim of this systematic review and meta-analysis was to investigate the efficacy of ginger supplementation on circulating levels of C-reactive protein (CRP), high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), soluble intercellular adhesion molecule (sICAM), and interleukin-6 (IL-6) concentrations in randomized controlled trials (RCTs). The search included PubMed-Medline, EMBASE, Scopus, Web of Science and Cochrane Library databases to identify randomized clinical trials on the effect of ginger supplementation on circulation levels of CRP, hs-CRP, IL-6, sICAM, and TNF-α published up until February 1st, 2020. We did not restrict articles based on language of publication. Standard mean differences and 95% confidence intervals were calculated for net changes in inflammatory mediators using a random-effects model. Sixteen RCTs comprising 1010 participants were found to be eligible for this meta-analysis. There was a significant reduction of circulating CRP (SMD: -5.11, 95% CI: -7.91, -2.30, I2 = 98.1%), hs-CRP (SMD: -0.88, 95% CI: -1.63, -0.12, I2 = 90.8%) and TNF-α levels (SMD: -0.85, 95% CI: -1.48, -0.21, I2 = 89.4%) following ginger supplementation. However, meta-analysis results did not show any significant impact of ginger supplementation on IL-6 (SMD: -0.45, 95% CI: -1.29, 0.38, I2 = 89.2%), and sICAM levels (SMD: -0.05, 95% CI: -0.36, 0.26, I2 = 00.0%). This systematic review and meta-analysis of RCTs demonstrates a significant impact of ginger in lowering circulating CRP, hs-CRP and TNF-α levels. Large-scale RCTs are still needed to draw concrete conclusions about the effect of ginger on other inflammatory mediators.

06
META-ANALYSIS Journal of the Academy of Nutrition and Dietetics (2019) PMID: 31519467 ↗
Efficacy of Ginger (Zingiber officinale) in Ameliorating Chemotherapy-Induced Nausea and Vomiting and Chemotherapy-Related Outcomes: A Systematic Review Update and Meta-Analysis.
Clinical Trial Synthesis 2019 Meta-Analysis published in Journal of the Academy of Nutrition and Dietetics involving n = 301 participants; statistical significance reported at p = 0.01 (OR 0.4). Key conclusion: CONCLUSIONS: Ginger supplementation might benefit chemotherapy-induced vomiting as well as fatigue.
View Original PubMed Abstract ↓

BACKGROUND: Ginger has been proposed as an adjuvant treatment for chemotherapy-induced nausea and vomiting. OBJECTIVE: The aim of this systematic review with meta-analyses is to evaluate, in adult cancer patients receiving chemotherapy, the effects of ginger supplementation dose and duration on the incidence, duration, and severity of chemotherapy-induced nausea and vomiting and outcomes related to chemotherapy-induced nausea and vomiting (eg, quality of life and fatigue), compared with placebo or standard antiemetic medication. METHOD: Five electronic databases were searched from database inception to April 2018. The quality of evidence was appraised with the Cochrane Risk of Bias tool and Grading of Recommendations, Assessment, Development, and Evaluation level. Data were pooled using Revman software. RESULTS: Eighteen articles were analyzed. The likelihood of acute vomiting was reduced by 60% with ginger supplementation ≤1 g/day for duration >3 days, compared with control groups (odds ratio 0.4, 95% CI 0.17 to 0.81; P=0.01; n=3 studies; n=3 interventions; n=301 participants; I2=20%; Grading of Recommendations, Assessment, Development, and Evaluation level: Moderate). The likelihood of fatigue was reduced by 80% with ginger supplementation of any dose for duration <3 days (odds ratio 0.2, 95% CI, 0.03 to 0.87; P=0.03; n=1 studies; n=2 interventions; n=219 participants; I2=0%; Grading of Recommendations, Assessment, Development, and Evaluation level: Low). No statistically significant association was found between ginger and likelihood of overall or delayed vomiting, likelihood or severity of nausea, or other outcomes related to chemotherapy-induced nausea and vomiting. CONCLUSIONS: Ginger supplementation might benefit chemotherapy-induced vomiting as well as fatigue. Due to clinical heterogeneity, this systematic review update found no association between ginger and chemotherapy-induced nausea and other chemotherapy-induced nausea and vomiting-related outcomes. The results of this systematic review and meta-analysis provide a rationale for further research with stronger study designs, adequate sample sizes, standardized ginger products, and validated outcome m

07
META-ANALYSIS Medicine (2019) PMID: 30921234 ↗
Dietary ginger as a traditional therapy for blood sugar control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Clinical Trial Synthesis 2019 Meta-Analysis published in Medicine involving n = 454 participants; statistical significance reported at p = 0.16 (MD 1.38). Key conclusion: However, dietary ginger significantly improved HbA1c from baseline to follow-up showing that this natural medici
View Original PubMed Abstract ↓

BACKGROUND: Ancient medical practitioners used to encourage dietary supplements and herbal medicine for the treatment of type 2 diabetes mellitus (T2DM). Ginger (Zingiber officinale), is a nontoxic spice with negligible side effects, and is considered safe by the food and drug administration. In this analysis, we aimed to systematically compare fasting blood sugar (FBS) and glycated hemoglobin (HbA1c) at baseline versus at follow-up in T2DM patients who consumed and who did not consume ginger. METHODS: A literature search was carried out through MEDLINE, Embase, the Cochrane Central, and www.ClinicalTrials.gov for English-published trials comparing glucose parameters in T2DM patients who were assigned to ginger consumption versus a control group. All the participants were patients with T2DM who were either assigned to ginger therapy (1600- 4000 mg daily) or to a control group. FBS and HbA1c were assessed in the ginger and control groups, respectively, from baseline to follow-up to observe any significant change. Weight mean difference (WMD) with 95% confidence intervals (CI) was calculated to represent the analysis which was carried out by the RevMan 5.3 software. RESULTS: Eight randomized trials consisting of a total number of 454 participants with T2DM were included in this analysis. At first, FBS was compared in patients with T2DM from baseline prior to ginger consumption until follow-up after ginger consumption. The results showed no significant difference in FBS (WMD: 1.38, 95% CI: [-0.53-3.30]; P = .16). For the T2DM patients who did not consume ginger, no significant difference in FBS was observed (WMD: -0.27, 95% CI: [-5.09-4.54]; P = .91). However, a significantly improved HbA1c from baseline to follow-up was observed in those participants with ginger consumption (WMD: 0.46, 95% CI: [0.09-0.84]; P = .02) whereas in the control group, no significant difference in HbA1c was observed (WMD: -0.23, 95% CI: [-0.60-0.14]; P = .22). CONCLUSION: This analysis involving patients with T2DM showed no significant difference in FBS with ginger consumption. However, dietary ginger significantly improved HbA1c from baseline to follow-up showing that this natural medici

08
CLINICAL STUDY The Cochrane database of systematic reviews (2016) PMID: 27000311 ↗
Dietary supplements for dysmenorrhoea.
Clinical Trial Synthesis 2016 Randomized Controlled Trial (RCT) published in The Cochrane database of systematic reviews involving n = 3,101 participants (OR 5.44). Key conclusion: Conventional treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and oral contraceptive pills (OCPs), which both reduce myometrial activity (contractions of the uterus).
View Original PubMed Abstract ↓

BACKGROUND: Dysmenorrhoea refers to painful menstrual cramps and is a common gynaecological complaint. Conventional treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and oral contraceptive pills (OCPs), which both reduce myometrial activity (contractions of the uterus). A suggested alternative approach is dietary supplements. We used the term 'dietary supplement' to include herbs or other botanical, vitamins, minerals, enzymes, and amino acids. We excluded traditional Chinese medicines. OBJECTIVES: To determine the efficacy and safety of dietary supplements for treating dysmenorrhoea. SEARCH METHODS: We searched sources including the Cochrane Gynaecology and Fertility Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, AMED, PsycINFO (all from inception to 23 March 2015), trial registries, and the reference lists of relevant articles. SELECTION CRITERIA: We included randomised controlled trials (RCTs) of dietary supplements for moderate or severe primary or secondary dysmenorrhoea. We excluded studies of women with an intrauterine device. Eligible comparators were other dietary supplements, placebo, no treatment, or conventional analgesia. DATA COLLECTION AND ANALYSIS: Two review authors independently performed study selection, performed data extraction and assessed the risk of bias in the included trials. The primary outcomes were pain intensity and adverse effects. We used a fixed-effect model to calculate odds ratios (ORs) for dichotomous data, and mean differences (MDs) or standardised mean differences (SMDs) for continuous data, with 95% confidence intervals (CIs). We presented data that were unsuitable for analysis either descriptively or in additional tables. We assessed the quality of the evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methods. MAIN RESULTS: We included 27 RCTs (3101 women). Most included studies were conducted amongst cohorts of students with primary dysmenorrhoea in their late teens or early twenties. Twenty-two studies were conducted in Iran and the rest were performed in other middle-income countries. Only one study address

09
RANDOMIZED TRIAL (RCT) Complementary therapies in medicine (2025) PMID: 40154579 ↗
Effect of aromatherapy with peppermint, ginger, and lavender on postoperative nausea severity after oral surgery under general anaesthesia: A single-blind randomized controlled trial.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Complementary therapies in medicine involving n = 182 participants; statistical significance reported at p = 0.001. Key conclusion: CONCLUSIONS: This study indicated that aromatherapy with peppermint, ginger, and lavender significantly improved patient satisfaction and severity of postoperative nausea after oral surgery under general anaesthesia.
View Original PubMed Abstract ↓

OBJECTIVES: This study aimed to examine whether aromatherapy with peppermint (Mentha piperita Mitcham), ginger (Zingiber officinale), and lavender (Lavandula angustifolia) reduces the severity of nausea in patients experiencing postoperative nausea after oral surgery under general anaesthesia. DESIGN: Single-centre, stratified (volatile inhaled anaesthetics used or not and sex, with balanced randomization), single-blind, placebo-controlled study conducted in Japan. SETTING: Hokkaido University Hospital. INTERVENTIONS: Totally, 182 patients were randomized into two groups of aromatherapy: aroma group comprising three essential oils-peppermint, ginger, and lavender-each diluted to 1 % (each dose as pure essential oil was 0.01 ml) and control group with purified water only. Of these, 32 patients in the aroma group and 25 in the control group complained of postoperative nausea and were treated with intervention. MAIN OUTCOME MEASURES: Change in nausea severity at the onset of postoperative nausea. RESULTS: Nausea severity before the intervention did not differ between groups. Aromatherapy significantly reduced nausea severity (p < 0.001). The percentages of antiemetics used were 30.77 % and 52.38 % in the aroma and control groups, respectively, with no significant difference. The aroma group showed significantly higher satisfaction (p < 0.001). No adverse events were observed during the study. CONCLUSIONS: This study indicated that aromatherapy with peppermint, ginger, and lavender significantly improved patient satisfaction and severity of postoperative nausea after oral surgery under general anaesthesia. Therefore, given the benefits of aromatherapy, it would be advantageous to consider a combination of measures that include aromatherapy, as one of the multimodal antiemetic measures. This trial was registered at the Japan Registry of Clinical Trials (jRCTs: 01121002).

10
RANDOMIZED TRIAL (RCT) Medicine (2024) PMID: 39259072 ↗
The efficacy and safety of ginger (Zingiber officinale) rhizome extract in outpatients with COVID-19: A randomized double-blind placebo-control clinical trial.
Clinical Trial Synthesis 2024 Randomized Controlled Trial (RCT) published in Medicine involving n = 84 participants. Key conclusion: However, this intervention demonstrated a safe profile of adverse events and reduced pulmonary infiltrate.
View Original PubMed Abstract ↓

BACKGROUND: Ginger, a potent antiviral, anti-inflammatory, and antioxidant remedy, is a potential therapeutic option for COVID-19. However, there was not enough clinical evidence about ginger and COVID-19. We evaluated the efficacy and safety of ginger on clinical and paraclinical features in outpatients with COVID-19. METHODS: In this randomized controlled trial, the outpatients with confirmed COVID-19 were randomly assigned in a 1:1 ratio to receive ginger (1000 mg 3 times a day for 7 days) or placebo. The primary outcome was viral clearance after the end of the intervention. Oxygen saturation (SPO2), body temperature, respiratory rate (RR), hospital admission, and the incidence of adverse events were also assessed. RESULTS: A total of 84 patients (42 in the ginger and 42 in the control groups) were randomized. The viral clearance was not statistically improved in the ginger group (41.6%) compared to the placebo group (42.8%). The findings indicated that SPO2, body temperature, and RR had no significant difference between the groups at the end of the intervention. The imaging finding indicated pulmonary infiltrate significantly reduced on the 7th day of the intervention in the ginger group. The percentage of patients with SPO2 <96% in the ginger group decreased over the study compared to the placebo group. Moreover, the need for hospital admission and the incidence of adverse drug events were not different between the groups over the follow-up period. CONCLUSIONS: Ginger had no significant impact on the clinical and paraclinical parameters of patients. However, this intervention demonstrated a safe profile of adverse events and reduced pulmonary infiltrate. TRIAL REGISTRATION: The trial was registered as IRCT20200506047323N1.

RELATED MONOGRAPHS

Related Monographs in This Category